Literature DB >> 25956660

Combination therapy with 308-nm excimer laser, topical tacrolimus, and short-term systemic corticosteroids for segmental vitiligo: A retrospective study of 159 patients.

Jung Min Bae1, Hyun Ju Yoo1, Hyub Kim2, Ji Hae Lee1, Gyong Moon Kim3.   

Abstract

BACKGROUND: Segmental vitiligo (SV) is characterized by a unilateral and localized distribution, early onset, and stable disease after rapid progression. And SV is often associated with poor response to various treatment modalities.
OBJECTIVE: We sought to evaluate the effectiveness of combination therapy with 308-nm excimer laser, topical tacrolimus, and short-term systemic corticosteroids for SV, and to search for factors associated with the treatment response.
METHODS: A retrospective interventional case-series study was performed on 159 patients with SV who were treated with the combination therapy for more than 3 months.
RESULTS: The rate of 75% or more repigmentation was 50.3% after a median treatment duration of 12.1 months; 36.5% and 13.8% of the patients showed nearly complete (75%-99%) and complete (100%) repigmentation, respectively. Multivariable analysis showed the following to be independent factors with poor response: disease duration longer than 12 months (odds ratio 0.372, 95% confidence interval 0.157-0.882, P = .025), poliosis (odds ratio 0.494, 95% confidence interval 0.247-0.988, P = .046), and plurisegmental subtype (odds ratio 0.175, 95% confidence interval 0.065-0.474, P = .001). LIMITATIONS: This was a retrospective study.
CONCLUSION: The combination therapy is effective for SV. Prolonged disease duration, poliosis, and plurisegmental subtype were shown to be independent prognostic factors of poor response in patients with SV.
Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  excimer laser; laser; segmental vitiligo; vitiligo

Mesh:

Substances:

Year:  2015        PMID: 25956660     DOI: 10.1016/j.jaad.2015.04.008

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  3 in total

1.  Fractional Er:YAG laser assisting topical betamethasone solution in combination with NB-UVB for resistant non-segmental vitiligo.

Authors:  Ru Yan; Jinping Yuan; Hongqiang Chen; Yuan-Hong Li; Yan Wu; Xing-Hua Gao; Hong-Duo Chen
Journal:  Lasers Med Sci       Date:  2017-07-14       Impact factor: 3.161

2.  Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.

Authors:  Lucy Y Liu; James P Strassner; Maggi A Refat; John E Harris; Brett A King
Journal:  J Am Acad Dermatol       Date:  2017-08-18       Impact factor: 11.527

3.  Efficacy of the Topical Calcineurin Inhibitors Tacrolimus and Pimecrolimus in the Treatment of Vitiligo in Infants Under 2 Years of Age: A Randomized, Open-Label Pilot Study.

Authors:  Wenting Hu; Yongping Xu; Yangyang Ma; Jiehao Lei; Fuquan Lin; Ai-E Xu
Journal:  Clin Drug Investig       Date:  2019-12       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.